"Ct"

In the early stages of atherosclerotic disease, most patients have almost no clinical symptoms and develop in a latent state of insidiousness.

On April 4, 2015, the 100-year-old active swimmer Mieko Nagaoka (living in Tabushi Town, Yamaguchi Prefecture, Japan) successfully completed the women's 1500-meter freestyle competition and became the world's first swimmer in the age group of 100-104.

In our intestines, there are a wide variety of intestinal microorganisms, which are called intestinal microflora. Many studies have proved that they play an extremely important role in maintaining normal digestion and absorption, regulating immunity and preventing pathogen invasion.

Nowadays, brain tumor is one of the common diseases, so it is necessary for us to learn more about it. What are the physical manifestations?

For brain cancer, the major obstacle to treatment is not the tumour, but the brain itself. How to break the "blood-brain barrier" and allow effective anti-cancer drugs to enter the brain to take effect has long been a key issue in brain cancer treatment. Recently, a new study has shown that a new type of pump can be implanted in brain cancer patients to safely break the blood-brain barrier and better treat brain cancer!

Was the omission of key data intentional or unintentional?

A new study has found that Istradefylline, a drug already approved to treat Parkinson's disease, not only reduces the toxicity associated with the chemotherapy drug cisplatin, but also boosts its cancer-fighting power, promising a potential treatment to reduce the side effects of chemotherapy.

Generally speaking, mild gastritis, i.e. superficial gastritis, does not increase the risk of gastric cancer, but if not adjusted in time, it may further develop into atrophic gastritis, which is a state of "precancerous lesion".

Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!